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Abstract
Background: The main source of HIV prevalence estimates are household and population-based surveys; however, high
refusal rates may hinder the interpretation of such estimates. The study objective was to evaluate whether population HIV
prevalence estimates can be adjusted for survey non-response using mortality rates.
Methodology/Principal Findings: Data come from the longitudinal Africa Centre Demographic Information System (ACDIS),
in rural South Africa. Mortality rates for persons tested and not tested in the 2005 HIV surveillance were available from
routine household surveillance. Assuming HIV status among individuals contacted but who refused to test (non-response) is
missing at random and mortality among non-testers can be related to mortality of those tested a mathematical model was
developed. Non-parametric bootstrapping was used to estimate the 95% confidence intervals around the estimates.
Mortality rates were higher among untested (16.9 per thousand person-years) than tested population (11.6 per thousand
person-years), suggesting higher HIV prevalence in the former. Adjusted HIV prevalence for females (15–49 years) was 31.6%
(95% CI 26.1–37.1) compared to observed 25.2% (95% CI 24.0–26.4). For males (15–49 years) adjusted HIV prevalence was
19.8% (95% CI 14.8–24.8), compared to observed 13.2% (95% CI 12.1–14.3). For both sexes (15–49 years) combined, adjusted
prevalence was 27.5% (95% CI 23.6–31.3), and observed prevalence was 19.7% (95% CI 19.6–21.3). Overall, observed
prevalence underestimates the adjusted prevalence by around 7 percentage points (37% relative difference).
Conclusions/Significance: We developed a simple approach to adjust HIV prevalence estimates for survey non-response.
The approach has three features that make it easy to implement and effective in adjusting for selection bias than other
approaches. Further research is needed to assess this approach in populations with widely available HIV treatment (ART).
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Introduction
About 33 million people were estimated to be HIV infected
worldwide in 2007 [1]. Despite the relative ease of diagnosing HIV
in adults, even in developed countries, the exact number of HIV
infected people is unknown because not all those contacted in
population surveys or surveillance systems will consent to HIV
testing [2]. Traditionally population estimates of HIV prevalence
in sub-Saharan Africa have been based on sentinel surveillance of
pregnant women attending antenatal clinics [3,4]. These data
remain widely available and used particularly in resource poor
settings, even though they are known to be biased due to lower
fertility of HIV positive women, and in some countries, by
unrepresentative selection of surveillance clinics [5].
Many other sources have been utilised in more recent times
such as regional or national household surveys [6], surveys among
high-risk populations [7,8], and population-based surveillance
studies [9]. A common feature of many of these surveys is non-
response, and a major concern for analysis and generalisation is
that the level of non-response can result in substantial biases in the
population HIV prevalence estimates [10]. This is of particular
concern if differential response rates are associated with specific
characteristics of the population or high-risk groups [11] and if
these data are used as inputs for deriving demographic, social and
economic impacts of HIV.
We previously examined mortality patterns and levels by HIV
infection status in rural South Africa using data from three annual
population-based HIV surveys conducted between 2003 and 2006
[12]. The age-adjusted mortality rate in 2005 among HIV-infected
adults (15–54 years) was reported at 53.9 deaths per 1,000 person-
years and among HIV uninfected adults as 4.6 deaths per 1,000
person-years; the age-adjusted mortality among adults contacted
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26.2 deaths per 1,000 person-years. In the analysis here we use
results of the HIV surveillance conducted by the Africa Centre in
2005 in the Umkhanyakude area of KwaZulu-Natal in which 58%
eligible people refused to participate in the surveillance, to suggest
a method for estimating the effect of gender-specific refusal rates
on HIV prevalence estimates.
High levels of test refusal are not unique to our research area,
and are common in HIV surveillance in South Africa, as
highlighted by Garcı ´a-Calleja et. al. [10]. A review of 20
population-based HIV prevalence surveys conducted between
2001 and 2005 in 19 sub-Saharan countries including South
Africa showed that the proportion of women who refused HIV
testing in the surveys ranged from 1% to 17% in 18 of the 19
countries but in South Africa the refusal rate was 30% (women)
and 35% (men) [10]. Further, within South Africa, a recent
nationally representative HIV survey found KwaZulu-Natal
province (where our study area is located) to have the highest
refusal to HIV testing at 37% (excluding absentees and non-
contacts) [13].
The aim of this paper is to describe a simple model which uses
mortality rates by HIV status to estimate HIV prevalence among
the population who refused to participate in the HIV surveillance.
The estimated prevalence among those who refused testing is then
used to adjust the overall prevalence in the total population in the
area. We use longitudinal demographic surveillance data from
rural South Africa to derive mortality rates for persons who tested
negative and positive during HIV surveillance in the same area in
2005 (testers), and for those who refused to participate in the 2005
HIV surveillance (non-testers) and for whom HIV status was thus
unknown to us. The model uses these mortality rates, and assumes
that mortality among the HIV status unknown group is a weighted
average of the mortality rates of those whose HIV status was
known, to estimate HIV prevalence among non-testers. Given that
the data are from a longitudinal demographic surveillance with
routine recording of deaths and the population at risk, the
resulting mortality data could provide a tool for adjusting HIV
prevalence in the study population to allow for refusal to test. This
method could be applicable in other demographic surveillance
sites, with relatively high rates of refusal to participate in HIV
testing but reliable mortality data for the population which can be
categorised by HIV status.
We compare observed HIV prevalence rates (from those who
consented to testing) to the adjusted HIV prevalence rates by age
and sex, and document a significant underestimate in the observed
prevalence rates.
Methods
Data sources
Data used in this analysis, and the initial work that motivated it,
come from the longitudinal Africa Centre Demographic Informa-
tion System (ACDIS), located in a largely rural district of
Umkhanyakude in northern KwaZulu-Natal, South Africa
(www.africacentre.com). The ACDIS has two components that
run parallel, the bi-annual household surveillance and the annual
individual surveillance. Demographic, social and economic data
have been collected since 2000 from key informants reporting on
all individual household members whether resident or non-
resident in the geographically well-defined surveillance area in
the household surveillance. In the individual surveillance, which
has been conducted since 2003, information on health and sexual
behaviours and a blood sample for HIV sero-status testing is
collected [14,15] from women 15–49 and men 15–54 years and a
dried blood spot is prepared from a finger prick. A broad based
HIV-1/HIV-2 ELISA test (Vironostika, Organon Teknika,
Boxtel, The Netherlands) is used to determine HIV status at the
Centre’s virology laboratory in Durban. All positive test results are
confirmed by a second ELISA (GAC-ELISA, Abbott, Abbott
Park, Illinois, USA) on the same sample. HIV infection is defined
by positive antibody status on both ELISAs, ‘HIV negative’ status
was defined by a negative first ELISA. Those not consenting to
HIV testing were classified as ‘HIV unknown’.
Ethics statement
During household visits with eligible individuals in the individual
surveillance, written informed consent is obtained for the collection,
storage and use in research of the blood sample and sexual
behaviour data. For household surveillance in which demographic
data are collected, oral informed consent is obtained from the key
informant who is usually the head of household, but in his or her
absence a competent adult household member. Field workers are
thoroughly trained every year and between the surveillance rounds
to ensure they offer both written and oral informed consent in a
uniform manner. Ethical approval for the individual surveillance
involving written consent and the household surveillance using oral
consent was obtained from the University of KwaZulu-Natal
Biomedical Research Ethics Committee.
Study sample
On January 1
st 2005 there were 84,964 individuals in 11,000
households under demographic surveillance; 21,472 resident
individuals (women and men 15–49 years) were contacted during
the 2005 HIV surveillance. Person-years of exposure were
estimated from the date at which an individual was HIV sero-
tested in 2005, or from the date of visit for individuals contacted
but who refused to participate in the HIV testing, and right-
censored on 31st December 2007 or by death, out-migration, or
household membership ending. Mortality rates were calculated by
dividing the number of deaths by the person-years of exposure for
three groups of people 1) HIV-negative, 2) HIV-positive and 3)
HIV status unknown (i.e. eligible resident individual was contacted
but not tested in the HIV surveillance).
We used non-parametric bootstrapping [16] with replacement
over 1,000 repetitions to estimate the 95% confidence intervals
associated with the HIV prevalence point estimates.
Presentation of a simple analytical model
We used reported mortality rates by HIV status (positive,
negative, unknown) to infer the HIV prevalence among those who
refused to participate in the HIV surveillance. We assumed that
mortality in the untested group is associated with the same factors
as in the tested group, and that apart from sex, age and HIV
status, mortality determinants were distributed in the untested
group in the same way as in the general population. The total
person-years lived in the group with unknown HIV status is
contributed partly by HIV infected persons and partly by
uninfected persons. Using this understanding and the assumptions
above, the simple analytical model can be presented as follows.
Allowing for mortality in the HIV negative, HIV positive and
HIV unknown group to vary by sex, s, age group, a, and time
period, t, and denoting mortality rates by M, and using the
subscripts p, n and u to denote the rates in persons with positive,
negative and unknown HIV status respectively:
Mu s,a,t ðÞ ~hu s,a,t ðÞ   Mp s,a,t ðÞ z 1{hu s,a,t ðÞ ½    Mn s,a,t ðÞ ð 1Þ
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HIV unknown population (of sex s, age a, time t) contributed by
infected persons. Another name for hu is the period HIV
prevalence in the untested population. hu(s,a,t) is unknown,
but all the mortality rates are known as Mp, Mn and Mu have
been measured in the demographic surveillance system. Thus, we
can solve for hu(s,a,t),:
hu s,a,t ðÞ ~
Mu s,a,t ðÞ {Mn s,a,t ðÞ
Mp s,a,t ðÞ {Mn s,a,t ðÞ
ð2Þ
We can also compare the period HIV prevalence in the
untested population hu(s,a,t), with period HIV prevalence in the
population whose status is known, hk(s,a,t), because the latter is
the person-years lived by those who tested positive as a fraction of
the person-years lived by positive and negative people.
hk s,a,t ðÞ ~
PYp s,a,t ðÞ
PYp s,a,t ðÞ zPYn s,a,t ðÞ
ð3Þ
An adjusted estimate, hw(s,a,t), of the HIV prevalence in the
whole population can be obtained as a weighted sum of the
estimated period HIV prevalence in the untested population and
the observed HIV prevalence among those who tested, weighting
by the person-years lived by the tested and the untested
populations.
hw s,a,t ðÞ ~
hu s,a,t ðÞ   PYu s,a,t ðÞ zhk s,a,t ðÞ   PYp s,a,t ðÞ zPYn s,a,t ðÞ

PYp s,a,t ðÞ zPYn s,a,t ðÞ zPYu s,a,t ðÞ
ð4Þ
Results
Overall, 59% of the 21,305 resident individuals did not provide
a sample for HIV testing in the 2005 round, and their HIV status
was marked as unknown; slightly more females 54% (n=6846)
than males 46% (n=5762) were in this unknown HIV status
category. Table 1 gives the consent rates by sex among eligible
adult residents in the ACDIS annual HIV surveys between 2003
and 2006. The proportion of men refusing to participate in the
HIV survey is higher than that of females in each year. By age
refusal to participate was relatively high in the age range 25–44
years, which is also a peak prevalence age range, which in itself is
likely to bias downwards the crude observed prevalence derived
from those tested. Figure 1 shows that those who did not test, for
males and for females, had an older age distribution than those
who tested, except for the 15–24 age group. The adjustment
method proposed here goes further than identifying differences in
age and sex composition of those who agree to participate and
those who refuse, looking within specific age- and sex- groups for
evidence of systematic differences between the tested and those
who refused.
A comparison of mortality rates by age and sex of the
population who tested versus the untested (Figure 2), suggests that
those who tested had higher mortality than those who did not.
Mortality rates were higher among the untested (16.9 per
thousand person-years) than the tested population (11.6 per
thousand person-years). By individual age groups and sex, females
who did not test had higher mortality than those who tested, with
the difference in the age group 45–49 being statistically significant
(Figure 2). A similar pattern was observed for males, except for the
age group 35–44 years, where those who did not test had a lower
mortality than those who tested. For both sexes combined, the
differences were marginally significant in the age groups 25–34
and 45–49 years respectively.
The individual age group differences do not reach statistical
significance, but overall mortality is significantly higher in the
untested group than in the tested, due not only to differences in the
age and sex composition of the tested and untested groups, as can
be shown by direct standardisation. Applying the age- and sex-
specific mortality rates in the tested group to the age-sex
composition of the total population we obtain a standardised
mortality rate of 13.7 per thousand (12.6, 14.7) whereas the
standardised rate resulting from applying the age- and sex- specific
rates of the untested population is 16.2 per thousand (15.1, 17.3).
Since the overall difference between the crude mortality rates in
the tested and untested populations is 4.8 per thousand (=15.9 -
11.1), as shown in Table 2, and the standardised difference is 2.5
per thousand (=16.2 - 13.7), we can attribute a difference of 2.3
per thousand to the age- and sex composition difference between
the tested and untested populations, and a difference of 2.5 per
thousand to actual mortality differences between the tested and
untested groups. Assuming that this mortality difference can be
explained by differences in HIV infection rates between the tested
and untested groups we investigate the implied HIV prevalence in
the untested group, and hence deduce an adjusted value for overall
prevalence, allowing for the effects of test refusal. We make these
estimates separately for females and males and by age group, with
95% confidence intervals estimated using a bootstrap resampling
method.
Prevalence estimates by age and sex, 2005
Using equation 4 above, results shown in Figure 3, the adjusted
HIV prevalence for females aged 15–49 years in 2005 was 31.6%
(95% CI 26.1–37.1) compared to an observed prevalence of 25.2%
(95% CI 24.0–26.4). For males aged 15–49 years the adjusted and
observed prevalence was 19.8% (95% CI 14.8–24.8) and 13.2%
(95% CI 12.1–14.3) respectively. For both sexes combined, the
adjusted HIV prevalence was 27.5% (95% CI 23.6–31.3),
compared to an observed prevalence among resident adults 15–
49 years who participated in the 2005 survey of 19.7% (95% CI
19.6–21.3). Figure 3 strongly suggests that the model presented
here results in a significant upwards adjustment of the observed
prevalence for males and for both sexes combined as the 95%
confidence limits for the adjusted prevalence estimate are outside
the confidence limits of the observed prevalence from those tested.
The adjusted HIV prevalence patterns by age for males and
females were broadly similar to the age pattern of the overall
adjusted prevalence for both sexes combined, as shown in Figure 4.
Prevalence was highest in the 25–34 years age range (Table 3).
Table 1. Participation rates among residents aged
15–54years in HIV testing, 2003–6.
Female Male Both sexes
Survey year n (%) n (%) n (%)
2003/4 12,259 59 9,010 56 21,269 58
2005 12,011 43 9,294 38 21,305 41
2006 12,537 40 9,452 34 21,989 38
doi:10.1371/journal.pone.0012370.t001
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those of unknown HIV status in particular, the adjusted
population HIV prevalence level after allowing for the likely
prevalence level among the non-testers suggests an under-
estimation in the observed HIV prevalence rate of around 7
percentage points for females, males and both sexes combined or a
relative difference of about 28% for females (32 vs 25), 54% for
males (20 vs 13) and 37% (27.5 vs 20) for both sexes. The relative
difference in the prevalence rates for males should however be
interpreted with caution as they were sensitive to the small
numbers of males participating in HIV testing in the surveillance
on one hand and their relatively high mortality on the other.
Discussion
In this analysis we set out to explore a simple model to obtain an
adjusted estimate of HIV prevalence in a population with a high
rate of non-response, using HIV surveillance data and where
Figure 1. Distribution of tested and untested by age and sex, ACDIS 2005 HIV survey.
doi:10.1371/journal.pone.0012370.g001
Figure 2. Mortality patterns by age and sex between tested and untested participants, 2005.
doi:10.1371/journal.pone.0012370.g002
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model presented here is that it does not rely on complex computer
simulations, or very detailed demographic data. It is simple to
apply in a DSS setting as the only data required are on HIV
testing status and mortality rates separately estimated by HIV
status. Other more complex procedures are available to address
non-response problems such as (multiple) imputations [17] and
regression equations [9]. However, these methods tend to rely on
individual-level variables such as mobility, marital status, work
status, alcohol use, number of partners, age at first sex,
Table 2. Person-years, mortality rates and HIV prevalence rates by age and sex, 2005.
Negative Positive UnTested Tested
Female PYO MR [95% CI] PYO MR [95% CI] PYO MR [95% CI] PYO MR [95% CI]
15–24 5,325 2.4 1.1 3.8 888 21.4 11.8 31.0 6,260 5.9 4.0 7.8 6,214 5.2 3.4 6.9
25–34 1,211 3.3 0.1 6.5 1,078 42.7 30.3 55.0 4,229 24.4 19.7 29.0 2,289 21.8 15.8 27.9
35–44 1,710 2.9 0.4 5.5 774 42.6 28.0 57.2 3,745 18.7 14.3 23.1 2,484 15.3 10.4 20.2
45–49 1,090 5.5 1.1 9.9 286 45.4 20.5 70.4 1,787 19.6 13.1 26.1 1,376 13.8 7.6 20.0
Total 9,336 3.0 1.9 4.1 3,027 36.7 29.8 43.5 16,021 15.3 13.4 17.2 12,363 11.2 9.4 13.1
Male
15–24 5,333 2.3 1.0 3.5 166 18.1 22.5 38.6 6,719 4.5 2.9 6.1 5,499 2.7 1.3 4.1
25–34 779 6.4 0.8 12.1 416 40.8 21.4 60.3 2,793 25.4 19.5 31.3 1,195 18.4 10.7 26.1
35–44 582 12.0 3.1 21.0 299 93.6 58.7 128.5 2,162 34.2 26.4 42.0 881 39.7 26.5 52.9
45–49 323 15.5 1.8 29.1 105 94.8 35.5 154.2 935 38.5 26.0 51.0 429 35.0 17.2 52.8
50–54 319 25.1 7.8 42.4 71 112.6 34.1 191.2 742 51.2 35.2 67.1 390 41.0 21.0 61.0
Total 7,337 5.0 3.4 6.7 1,058 62.4 47.3 77.4 13,352 18.6 16.3 21.0 8,394 12.3 9.9 14.6
Both sexes
15–24 10,658 2.3 1.4 3.3 1,054 20.9 12.2 29.6 12,979 5.2 3.9 6.4 11,713 4.0 2.9 5.2
25–34 1,990 4.5 1.6 7.5 1,494 42.2 31.7 52.6 7,022 24.8 21.1 28.5 3,485 20.7 15.9 25.4
35–44 2,292 5.2 2.3 8.2 1,073 56.8 42.5 71.2 5,907 24.4 20.4 28.4 3,366 21.7 16.7 26.7
45–49 1,413 7.8 3.2 12.4 392 58.7 34.5 82.9 2,722 26.1 20.0 32.1 1,805 18.8 12.5 25.2
Total 16,354 3.5 2.6 4.4 4,014 42.1 35.8 48.5 28,631 15.9 14.5 17.4 20,368 11.1 9.6 12.5
PYO=Person-years of observation; M=mortality rate per 1000 person-years of observation.
doi:10.1371/journal.pone.0012370.t002
Figure 3. Observed and Adjusted HIV prevalence rate in adults 15–49 years by sex, 2005.
doi:10.1371/journal.pone.0012370.g003
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reporting bias than mortality data that we use in our method.
These individual-level variables, unlike mortality, are in addition
not routinely or uniformly collected in many surveillance sites.
Furthermore, unlike the individual-level analysis that is adopted in
most DHS to adjust the prevalence estimates for test refusal which
require predicting the probability of an individual non-tester being
infected based on his/her peculiar characteristics, the method we
propose here is an aggregate model which does not suffer from the
limitations of individual-level analyses. Our mortality differentials
suggest that non-testers are significantly different from testers, and
thus our results are different to Mishra et. al. because a) non-testers
appear to have relatively higher prevalence rates than testers and
b) we have a higher refusal rate than any of the studies cited by
Mishra et. al.
Figure 4 shows the confidence intervals to be relatively narrow
for the overall adjusted rate, but very wide in the age groups 25–34
and 45–49 years, suggesting greater uncertainty in the adjusted
estimates for these age groups. This would suggest that prevalence
rates in the age groups 25–34 and 45–49 years are more of an
under-estimate than in other age-groups. The former age group is
associated with higher HIV prevalence but relatively lower
participation in HIV surveillance, while the latter age group is
associated with high mortality and generally high participation
rates in HIV testing. Particularly for the 45–49 years age group,
the high uncertainty could be partially explained by the small
Figure 4. HIV prevalence rate in adults 15–49 years untested and overall adjusted, 2005.
doi:10.1371/journal.pone.0012370.g004
Table 3. Observed and Adjusted HIV prevalence rate in adults 15–49 years, 2005.
Observed HIV pre-valence Adjusted prevalence among untested Adjusted overall HIV prevalence
Age group Prevalence (%) 95% CI Prevalence (%) 95% CI Prevalence (%) 95% CI
15–24 9.0% 8.3 10.0 14.9 3.0 26.7 12.2 5.9 18.5
25–34 42.9% 41.5 46.4 53.6 34.9 72.2 50.4 37.8 63.0
35–44 31.9% 30.9 35.7 37.2 24.0 50.4 35.8 27.3 44.3
45–49 21.7% 19.6 24.7 39.8 16.9 62.8 33.0 18.9 47.0
Total 19.7% 19.6 21.3 32.3 25.7 38.8 27.5 23.6 31.3
doi:10.1371/journal.pone.0012370.t003
Adjusting HIV Prevalence
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12370numbers. The overall adjusted HIV prevalence rates for females
and males as well as by age from application of our proposed
model were consistently above the upper confidence limits of the
observed prevalence rates. We show from this approach that the
prevalence in those who consented to HIV testing in the 2005
survey under estimated the prevalence in the population as a
whole by around seven percentage points. Our results suggesting
the true HIV prevalence in the study population is likely under-
estimated if only the observed data are considered, are in line with
other studies [6,9].
Data from our research site shows that relative to individuals
who had tested negative in the first HIV round, persons who had
tested positive were 23% significantly less likely to test again in the
2005 survey round. A recent study using longitudinal data from
Malawi to examine the effect of prior knowledge of being HIV
infected on consent to subsequent HIV surveillance testing found
that Malawians who knew their positive HIV status were five times
more likely to refuse participation than those who had tested
negative previously [18]. A positive association between age, urban
residence, being employed and absenteeism from home with
refusal to participate in HIV sero-testing survey has also been
shown [6,19]. We are therefore confident that the suggested
under-estimate in the observed HIV prevalence rate is valid, and
our mortality-based procedure provides a reasonable method of
adjustment of the observed HIV prevalence rates.
Our approach may have utility even in the context of HIV
treatment (ART), although it would require making a further
assumption that the proportion of infected people on treatment
amongst those testing and those refusing to test in the surveillance
round are broadly similar. An alternative approach would be to
divide the population into four groups rather than three: those
tested HIV negative, those tested HIV positive but not on
treatment, those on ART regardless of whether they consented to
testing or not, and those who did not test and were not on ART.
Such an approach would only be feasible if ART clinic data could
be linked to demographic surveillance data. There is a future
opportunity in the study setting with the increasing availability of
HIV treatment [20] to validate this model post-HIV treatment
roll-out.
Limitations
A limitation of this simple model is that it is dependent on the
population consenting to participate in HIV surveillance not being
significantly different from those not consenting with respect to
factors other than HIV that determine mortality. Non-response is
a common feature of population-based HIV surveys [9,10,11]. If
non-response is particularly high among a select group or persons
with particular characteristics, that pre-dispose them to lower or
higher mortality from HIV, such as disease stage [21], or causes
other than HIV it is likely to bias this adjustment procedure. This
is why it would be useful to apply the adjustment procedure in
more homogenous social categories by breaking down by
residence and education - this was not possible in the present
study because of small numbers. Even data from nationally
representative studies such as by the Human Sciences Research
Council of South Africa (HSRC) [13] also suffer from problems of
test refusal which is likely to bias their results. But since such
studies tend to be cross-sectional, the mortality-based method we
propose here can not be applied to estimate the extent of bias. In
addition, it cannot be used to adjust cross-sectional sources of
national HIV prevalence data where no prospective adult
mortality data are available, for example the demographic and
health surveys or the South African HSRC national HIV survey.
Another major limitation of this analysis was the use of
information on 29% of deaths (and accounting for 36% of the
exposure) with known HIV status to adjust the HIV prevalence in
the nearly two-thirds of population with unknown HIV status.
This was a result of the generally high refusal rate to participate
in HIV surveillance in our study population. This may have
biased our findings. We examined these mortality data in detail
since the proposed method so crucially depends on them to check
our assumption that the same type of reporting bias affects all
ages and whether mortality rate differentials might be accounted
for by differences in age and sex composition in the tested and
untested populations. The chi-square test (not shown) for the
differences in mortality rates between tested and untested in
Table 2, does not attain significance in individual age groups
(because of relatively small numbers), however, for both sexes
combined, and for males and females of all ages (except for males
aged 35–44) the mortality rates in the untested group are higher
than in the tested group. Furthermore, the fact that the
relationship goes in the same direction for every age-sex group
(except one) adds support to the appropriateness of using the
mortality rates to adjust HIV prevalence. We further urge caution
in the interpretation of mortality rates and the adjusted figures
particularly at the older age groups and for males as the small
numbers may have affected the mortality estimates particularly at
the older age groups. The availability of information to assess
tested person years of observation (Table 2) as a proportion of all
person years also assists in avoiding over-interpretation. Despite
these limitations the proposed method remains methodologically
sound.
In conclusion, after adjusting for the untested population, there
was very little change in the pattern of age specific HIV prevalence
rates for women or men, but a significant difference between the
overall adjusted and observed prevalence (7 percentage points in
absolute terms).
Our approach renders itself to easy application and should be
relevant for demographic surveillance sites such as our own that
have conducted HIV prevalence surveys and can classify ensuing
deaths by HIV status. Application of this method in populations
with wide availability of HIV treatment (ART) may require
identifying people on ART as a separate group. Our approach to
adjusting for selection effects by conditioning on observed factors
has three highlighted advantages over other approaches. First,
only aggregate mortality and HIV prevalence data are needed.
Second, HIV prevalence is highly associated with mortality [12],
and third, the approach is easily applicable even in settings with
only one HIV sero-survey but longitudinal mortality follow-up of
those who participated in the sero-survey and those who refused.
These features make our approach easy to implement and effective
in adjusting for selection bias than other approaches. Given the
very high proportion of our population with unknown HIV status
and limitations of our mortality data in general, there is an
opportunity for validation of the proposed adjustment method in
this analysis in other surveillance sites with lower refusal rates and
reliable mortality data. This method appears to be methodolog-
ically sound hence such a validation exercise will help to determine
its reliability and robustness.
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